That’s where companies like Behavioral Signals, the emotion cognitive AI provider which develops technology to analyze human behavior from...
Read more
Biotech startup Vivodyne is planning to revolutionize drug development with an AI-powered robot that can grow, dose, and analyze...
Read more
Allergic and autoimmune diseases were first described in the early 1900s, which Holoclara said is the same time that...
Read more
Delpor is sketching out late-stage clinical trial plans for its drug-device combination implant DLP-114 (risperidone) in schizophrenia. After presenting topline...
Read more
MemVerge is a company that is delivering the world’s first Memory-Converged Infrastructure system, built with proprietary software technology. Pulse...
Read more
Foldax announced completion of enrollment in the Indian clinical trial of the TRIA™ polymer surgical mitral heart valve.
Read more
Vivodyne announced the close of $38 million in total seed financing, led by Khosla Ventures, with participation from Kairos...
Read more
Delpor announced topline results of its DLP-114 Phase 1b/2a clinical study during which schizophrenia patients received treatment for up...
Read more
MemVerge and Sentieon announced a collaboration to accelerate next-generation sequencing (NGS) in the public cloud. MemVerge and Sentieon integrated...
Read more
Behavioral Signals has announced its work in the federal marketplace. “AI is ushering in a profound transformation in the...
Read more